BIOCRYST PHARMACEUTICALS, INC. Financials BioCryst Pharmaceuticals, Inc.
Equities
BCRX
US09058V1035
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.32 USD | -0.37% |
|
+19.55% | -11.19% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 531.5 | 1,315 | 2,492 | 2,140 | 1,227 | 1,098 | - | - |
| Enterprise Value (EV) 1 | 479.9 | 1,198 | 2,124 | 2,140 | 1,654 | 1,332 | 1,357 | 1,189 |
| P/E ratio | -3.67 x | -6.83 x | -13.4 x | -8.63 x | -5.08 x | -8.73 x | -13.3 x | 20.7 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 10.9 x | 73.8 x | 15.9 x | 7.9 x | 3.7 x | 2.74 x | 2.26 x | 1.89 x |
| EV / Revenue | 9.83 x | 67.3 x | 13.5 x | 7.9 x | 4.99 x | 3.32 x | 2.79 x | 2.05 x |
| EV / EBITDA | -4.86 x | -6.88 x | -12 x | -14.6 x | -16.2 x | -25.2 x | -168 x | - |
| EV / FCF | -5.34 x | -7.28 x | -14.7 x | -13.1 x | -17 x | 45.9 x | 13.7 x | 7.2 x |
| FCF Yield | -18.7% | -13.7% | -6.81% | -7.63% | -5.88% | 2.18% | 7.31% | 13.9% |
| Price to Book | 10.4 x | -68.5 x | -23.9 x | -7.32 x | -2.71 x | -2.22 x | -2.1 x | -2.16 x |
| Nbr of stocks (in thousands) | 154,059 | 176,566 | 179,936 | 186,424 | 204,809 | 206,377 | - | - |
| Reference price 2 | 3.450 | 7.450 | 13.85 | 11.48 | 5.990 | 5.320 | 5.320 | 5.320 |
| Announcement Date | 3/5/20 | 2/25/21 | 2/23/22 | 2/21/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 48.84 | 17.81 | 157.2 | 270.8 | 331.4 | 401.3 | 486.2 | 580.1 |
| EBITDA 1 | -98.73 | -174 | -176.9 | -147 | -102.1 | -52.82 | -8.067 | - |
| EBIT 1 | -99.46 | -174.8 | -177.7 | -148.4 | -103.7 | -36.84 | 27.73 | 117.1 |
| Operating Margin | -203.66% | -981.12% | -113.08% | -54.81% | -31.29% | -9.18% | 5.7% | 20.19% |
| Earnings before Tax (EBT) 1 | -108.9 | -182.8 | -181.8 | -244.4 | -226.2 | -129.7 | -73.96 | 62.04 |
| Net income 1 | -108.9 | -182.8 | -184.1 | -247.1 | -226.5 | -127.7 | -73.96 | 55.4 |
| Net margin | -222.99% | -1,026.35% | -117.11% | -91.25% | -68.36% | -31.83% | -15.21% | 9.55% |
| EPS 2 | -0.9400 | -1.090 | -1.030 | -1.330 | -1.180 | -0.6091 | -0.4001 | 0.2575 |
| Free Cash Flow 1 | -89.93 | -164.6 | -144.5 | -163.2 | -97.31 | 29 | 99.14 | 165.2 |
| FCF margin | -184.14% | -924.12% | -91.97% | -60.26% | -29.36% | 7.23% | 20.39% | 28.49% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 298.27% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 2/25/21 | 2/23/22 | 2/21/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 47.16 | 49.92 | 65.53 | 75.83 | 79.54 | 68.78 | 82.49 | 86.74 | 93.4 | 92.76 | 98.45 | 103.3 | 107.9 | 110 | 117.7 |
| EBITDA | -52.01 | -49.64 | -34.39 | -17.06 | -45.92 | -28.01 | - | - | -42.25 | - | - | - | - | - | - |
| EBIT 1 | -52.18 | -49.96 | -34.72 | -17.44 | -46.31 | -28.42 | -20.7 | -11.92 | -42.67 | -14.49 | -10.15 | -5.946 | -4.926 | -3.668 | 0.645 |
| Operating Margin | -110.64% | -100.07% | -52.98% | -23.01% | -58.22% | -41.31% | -25.1% | -13.74% | -45.68% | -15.62% | -10.31% | -5.75% | -4.57% | -3.34% | 0.55% |
| Earnings before Tax (EBT) 1 | -15.53 | -73.92 | -58 | -41 | -71.47 | -52.66 | -74.59 | -35.82 | -63.16 | -35.01 | -32.55 | -29.74 | -28.09 | -22.92 | -18.6 |
| Net income 1 | -17.78 | -74.2 | -58.86 | -42.52 | -71.54 | -53.33 | -75.33 | -36.15 | -61.73 | -35.38 | -32.55 | -29.61 | -28.84 | -22.92 | -18.6 |
| Net margin | -37.7% | -148.62% | -89.82% | -56.08% | -89.94% | -77.54% | -91.31% | -41.67% | -66.09% | -38.14% | -33.06% | -28.65% | -26.73% | -20.84% | -15.81% |
| EPS 2 | -0.1000 | -0.4000 | -0.3200 | -0.2300 | -0.3800 | -0.2800 | -0.4000 | -0.1900 | -0.3100 | -0.1700 | -0.1801 | -0.1445 | -0.1409 | -0.1050 | -0.0800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/23/22 | 5/5/22 | 8/4/22 | 11/1/22 | 2/21/23 | 5/3/23 | 8/3/23 | 11/2/23 | 2/26/24 | 5/6/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 427 | 234 | 259 | 91.1 |
| Net Cash position 1 | 51.6 | 117 | 368 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -4.181 x | -4.43 x | -32.07 x | - |
| Free Cash Flow 1 | -89.9 | -165 | -145 | -163 | -97.3 | 29 | 99.1 | 165 |
| ROE (net income / shareholders' equity) | -249% | -1,925% | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -67.6% | -71.7% | -52% | - | -42.5% | -32.1% | -25.2% | -15.5% |
| Assets 1 | 161.1 | 255 | 354 | - | 533.5 | 397.5 | 293.3 | -358 |
| Book Value Per Share 2 | 0.3300 | -0.1100 | -0.5800 | -1.570 | -2.210 | -2.400 | -2.540 | -2.460 |
| Cash Flow per Share 2 | -0.7800 | -0.8200 | -0.7900 | -0.8700 | -0.5000 | -0.2100 | 0.0300 | - |
| Capex 1 | 0.34 | 0.51 | 2.39 | 1.35 | 2.17 | 0.36 | 0.36 | 0.37 |
| Capex / Sales | 0.7% | 2.89% | 1.52% | 0.5% | 0.65% | 0.09% | 0.07% | 0.06% |
| Announcement Date | 3/5/20 | 2/25/21 | 2/23/22 | 2/21/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
5.32
USD
Average target price
14
USD
Spread / Average Target
+163.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.19% | 1.1B | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- BCRX Stock
- Financials BioCryst Pharmaceuticals, Inc.